Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

EDIT

Editas Medicine Inc

May 10 • 04:00PM ET

5.32

Dollar change -0.24
Percentage change -4.32	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VXF VBK IWN LABU IBB DFAT VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.10	Insider Own	0.32%	Shs Outstand	82.24M	Perf Week	-6.17%
Market Cap	437.52M	Forward P/E	-	EPS next Y	-2.62	Insider Trans	-27.33%	Shs Float	81.97M	Perf Month	-19.15%
Income	-166.13M	PEG	-	EPS next Q	-0.69	Inst Own	79.48%	Short Float	25.02%	Perf Quarter	-28.59%
Sales	69.41M	P/S	6.30	EPS this Y	-31.63%	Inst Trans	2.33%	Short Ratio	10.18	Perf Half Y	-36.67%
Book/sh	3.58	P/B	1.49	EPS next Y	1.32%	ROA	-36.74%	Short Interest	20.50M	Perf Year	-46.75%
Cash/sh	3.60	P/C	1.48	EPS next 5Y	1.70%	ROE	-54.30%	52W Range	4.91 - 11.91	Perf YTD	-47.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.88%	ROI	-52.54%	52W High	-55.33%	Beta	2.07
Dividend TTM	-	Quick Ratio	4.60	Sales past 5Y	101.57%	Gross Margin	91.46%	52W Low	8.35%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	4.60	EPS Y/Y TTM	33.95%	Oper. Margin	-266.85%	RSI (14)	38.95	Volatility	7.60% 6.01%
Employees	265	Debt/Eq	0.12	Sales Y/Y TTM	204.54%	Profit Margin	-239.36%	Recom	2.29	Target Price	14.79
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-6.27%	Payout	-	Rel Volume	0.81	Prev Close	5.56
Sales Surprise	-89.81%	EPS Surprise	-21.48%	Sales Q/Q	-88.48%	Earnings	May 08 BMO	Avg Volume	2.01M	Price	5.32
SMA20	-4.16%	SMA50	-23.97%	SMA200	-34.87%	Trades		Volume	1,637,439	Change	-4.32%

Date	Action	Analyst	Rating Change	Price Target Change
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$7
Oct-24-23	Upgrade	Citigroup	Neutral → Buy	$11
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral	$8
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy	$9 → $17
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform	$17
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-13-22	Initiated	Citigroup	Neutral	$11
Dec-06-22	Resumed	Credit Suisse	Neutral	$13
Nov-18-22	Downgrade	Oppenheimer	Outperform → Perform	$28 → $12
Nov-18-22	Downgrade	Credit Suisse	Outperform → Neutral	$25 → $13
Sep-29-22	Initiated	BofA Securities	Neutral	$18
Oct-19-21	Initiated	SVB Leerink	Mkt Perform	$41
Sep-24-21	Initiated	Stifel	Hold	$65
Sep-10-21	Upgrade	Oppenheimer	Perform → Outperform	$42 → $80
Aug-09-21	Upgrade	Truist	Hold → Buy	$45 → $80
Aug-05-21	Upgrade	Evercore ISI	Underperform → Outperform	$20 → $60
Jun-04-21	Resumed	Robert W. Baird	Outperform	$44
May-04-21	Initiated	RBC Capital Mkts	Sector Perform	$40
Apr-16-21	Initiated	Goldman	Sell	$20

Show Previous Ratings

May-10-24 06:00AM	Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-09-24 03:38PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.43%
01:12PM	1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? (Motley Fool)
12:40PM	Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down (Zacks)
11:33AM	Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating (MT Newswires)
08:00AM	Loading…
08:00AM	Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight (MT Newswires)
May-08-24 10:33PM	Q1 2024 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents) -11.36%
11:55AM	EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:25AM	Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:29AM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces First Quarter 2024 Results and Business Updates (GlobeNewswire)
May-02-24 07:00AM	Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
May-01-24 10:46AM	Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration (MT Newswires)
08:00AM	Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration (GlobeNewswire)
Apr-29-24 10:26AM	12 Under-the-Radar Stocks With Massive Upside for 2024 (Insider Monkey)
10:00AM	Loading…
Apr-26-24 10:00AM	Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-22-24 04:31PM	Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Mar-29-24 11:30AM	Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report? (Zacks)
Mar-07-24 03:31AM	1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. (Motley Fool)
Mar-05-24 11:52PM	Insider Sells Shares of Editas Medicine Inc (EDIT) (GuruFocus.com) -7.86%
Mar-04-24 10:30AM	1 Beaten-Down Stock With 55% Upside, According to Wall Street (Motley Fool) -5.79%
Mar-02-24 09:49PM	Why Editas Medicine Stock Soared as Much as 42% Higher This Week (Motley Fool)
Feb-29-24 11:26AM	Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.12%
08:42AM	Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up (Zacks)
Feb-28-24 11:15PM	Q4 2023 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents) +24.94%
08:10AM	Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:35AM	Editas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing Trials (GuruFocus.com)
07:08AM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates (GlobeNewswire)
Feb-21-24 07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
09:55AM	Loading…
Feb-19-24 09:55AM	Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade (Zacks)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-06-24 12:00PM	What Makes Editas (EDIT) a New Buy Stock (Zacks)
Jan-31-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-24 08:45AM	2 Under-the-Radar Stocks With Incredible Upside Potential (Motley Fool)
Jan-21-24 09:37AM	Could Editas Medicine Become the Next CRISPR Therapeutics? (Motley Fool)
Jan-17-24 12:04PM	7 Mighty Healthcare Stocks Changing the Game of Medicine (InvestorPlace)
Jan-15-24 05:19AM	Down 88%, Could Editas Medicine Be a Good Investment Now? (Motley Fool)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace)
Jan-08-24 08:15AM	Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference (GlobeNewswire)
07:45AM	Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics (Motley Fool)
Jan-03-24 07:00AM	Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.11%
Jan-02-24 10:15AM	Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why (Zacks)
Dec-23-23 08:02AM	Editas Just Caught a Break Thanks to Vertex Pharmaceuticals (Motley Fool)
Dec-14-23 08:32AM	Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6% (Zacks)
06:30AM	Editas cashes in on CRISPR patent with Vertex deal (BioPharma Dive)
Dec-13-23 05:12PM	S&P 500 Gains and Losses Today: Regional Banks Get a Boost From the Fed (Investopedia) +5.69%
04:06PM	Vertex Stock Hits Record High on Phase 2 Study Results and Gene-Editing Deal (Investopedia)
12:30PM	Midday Movers: Vertex Surges on Gene-Editing Deal, Pfizer Falls on Guidance Miss (Investopedia)
09:00AM	Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 (GlobeNewswire)
Dec-11-23 01:22PM	ASH23: Pharma branding, Editas high bar and clinical trial diversity (BioPharma Dive) -5.71%
12:00PM	Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar (GlobeNewswire)
Dec-10-23 11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Dec-05-23 07:00AM	1 Promising Stock Down 66% That Could Skyrocket in 2024 (Motley Fool)
Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
Nov-22-23 06:30AM	Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year (InvestorPlace)
Nov-20-23 05:43PM	The 3 Best Gene Editing Stocks on the Frontier of Medicine (InvestorPlace) +10.84%
05:36AM	2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street (Motley Fool)
Nov-16-23 03:25PM	3 Long-Term Growth Stocks Analysts Are Bullish On (InvestorPlace)
Nov-09-23 03:37PM	3 Biotech Stocks That Are Betting on the Future of Gene Editing (InvestorPlace) -6.31%
Nov-06-23 09:00AM	Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
Nov-05-23 05:51PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 08:45AM	Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +18.21%
08:34AM	Editas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45. ... (GuruFocus.com)
07:17AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Third Quarter 2023 Results and Business Updates (GlobeNewswire)
Nov-02-23 09:12AM	Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar (GlobeNewswire)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-27-23 07:00AM	Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
Oct-24-23 09:51AM	Foot Locker downgraded, Amazon initiated: Wall Street's top analyst calls (The Fly) +5.12%
01:53AM	The Trade Desk cleans up; DraftKings 'stronger than ever': 5 big analyst picks (Investing.com)
Oct-18-23 11:05AM	3 Gene Editing Stocks to Generate Super-Charged Gains (InvestorPlace)
09:52AM	Arm initiated, SQM downgraded: Wall Street's top analyst calls (The Fly)
09:30AM	1 Risky Biotech Stock to Consider Buying, and 1 to Avoid (Motley Fool)
Oct-17-23 11:47AM	Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD (Zacks) -6.20%
Oct-16-23 08:00AM	Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease (GlobeNewswire)
Oct-07-23 10:07AM	Is Editas Stock a Buy Now? (Motley Fool)
Oct-05-23 10:07AM	Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things (Motley Fool)
Oct-02-23 10:00AM	Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics (Motley Fool) -8.46%
Sep-29-23 11:21AM	Why Editas Medicine Stock Is Soaring Today (Motley Fool) +12.72%
Sep-28-23 06:27AM	The Petri Dish: Ginkgo, Pfizer sign $331M deal; Leqembi OK'd in Japan (American City Business Journals)
Sep-25-23 04:30PM	Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer (GlobeNewswire) -9.49%
09:00AM	Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer (GlobeNewswire)
Sep-23-23 08:45AM	1 Gene Editing Stock to Buy Now, and 1 to Sell (Motley Fool)
Sep-08-23 05:03AM	Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Sep-07-23 11:30AM	Ligand (LGND) Down 8.8% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-01-23 11:31AM	Why Is Editas (EDIT) Down 4.3% Since Last Earnings Report? (Zacks)
Aug-30-23 09:00AM	Editas Medicine Announces Upcoming Investor Events (GlobeNewswire)
Aug-28-23 07:00AM	Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer (GlobeNewswire)
Aug-23-23 08:25AM	These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street (Motley Fool)
Aug-04-23 12:38PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 11:45AM	Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus (Zacks)
Aug-02-23 08:25AM	Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +5.66%
07:13AM	Editas: Q2 Earnings Snapshot (AP Finance)
07:00AM	Editas Medicine Announces Second Quarter 2023 Results and Business Updates (GlobeNewswire)
Jul-31-23 07:02AM	The past three years for Editas Medicine (NASDAQ:EDIT) investors has not been profitable (Simply Wall St.)
Jul-27-23 09:00AM	Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization (PR Newswire)
06:29AM	The Petri Dish: Pfizer ends Syros collab; Editas hires 37-year Biogen vet (American City Business Journals)
Jul-26-23 07:00AM	Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update (GlobeNewswire)
Jul-25-23 08:00AM	Editas Medicine Reports Inducement Grant to New Chief Scientific Officer (GlobeNewswire)

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Neill Gilmore Neil	CEO	Mar 05 '24	Sale	9.42	77,824	732,884	327,470	Mar 05 08:00 PM
Mei Baisong	SVP, CHIEF MEDICAL OFFICER	Mar 04 '24	Sale	9.42	20,327	191,425	141,543	Mar 05 07:54 PM
Eaton Bruce	EVP, CBO AND CTO	Dec 05 '23	Sale	10.90	103	1,122	74,791	Dec 07 04:30 PM
Eaton Bruce	EVP, CBO AND CTO	Nov 14 '23	Sale	8.21	695	5,706	74,894	Nov 16 04:30 PM
Eaton Bruce	EVP, CBO AND CTO	Nov 07 '23	Sale	8.40	139	1,168	75,589	Nov 09 04:31 PM
Eaton Bruce	EVP, CBO AND CTO	Sep 06 '23	Sale	8.82	103	908	75,728	Sep 07 04:59 PM
Eaton Bruce	EVP, CBO AND CTO	Aug 11 '23	Sale	8.59	702	6,033	75,831	Aug 15 04:30 PM
Eaton Bruce	EVP, CBO AND CTO	Aug 08 '23	Sale	8.39	141	1,183	76,533	Aug 10 04:30 PM
Mei Baisong	SVP, CHIEF MEDICAL OFFICER	Jul 19 '23	Sale	8.80	4,317	37,990	72,055	Jul 21 04:30 PM
O'Neill Gilmore Neil	CEO	Jun 05 '23	Sale	9.50	6,486	61,638	130,169	Jun 07 04:30 PM
Eaton Bruce	EVP, CBO AND CTO	Jun 05 '23	Sale	9.50	105	998	76,674	Jun 07 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EDIT

Editas Medicine Inc

Upgrade your FINVIZ experience